A First-in-human Study of 3H-10000 in Patients With Unresectable or Metastatic Solid Tumors
A Phase I/II Study of 3H-10000 (an Anti-FGFR2b Antibody-Drug Conjugate) in Subjects With Unresectable or Metastatic Advanced Solid Tumors
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Shuchao Wu
- Phone Number: 0086-21-50895559
- Email: shuchao.wu@3hpharma.com
Study Locations
-
-
Beijing Municipality
-
Beijing, Beijing Municipality, China, 100142
- Recruiting
- Beijing Cancer Hospital
-
Contact:
- Lin Shen, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Subjects must be willing and able to sign the ICF and to adhere to the study visit schedule and other protocol requirements.
- Male or female subjects aged ≥18 years at the time of signing the ICF.
- According to RECIST v1.1, there is at least one measurable lesion.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0-1 point.
- Life expectancy of ≥3 months.
Exclusion Criteria:
- Meningeal diseases or carcinomatous meningitis.
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage every two weeks or more frequently.
- Having received treatment with other investigational drugs within 4 weeks prior to the first dose of the study drug.
- Any AEs induced by prior anti-tumor therapy having not resolved to Grade 1 or lower (except for alopecia or any other Grade 2 AEs assessed by the investigator as not being associated with any safety risk).
- Any corneal or retinal disease/keratopathy assessed by the investigator as of clinical significance, including but not limited to bullous/band keratopathy, corneal abrasion, inflammation/ulceration, and keratoconjunctivitis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Stage I - dose escalation
Dose escalation of 3H-10000 in patients with advanced solid tumors.
|
3H-10000 will be administered by infusion Q2W in 28-day cycles.
|
|
Experimental: stage II - expansion
Expansion evaluating the recommended dose and schedule of 3H-10000 identified from Stage I.
|
3H-10000 will be administered by infusion Q2W in 28-day cycles.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dose Escalation Phase:Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Up to approximately 2 years
|
Number of participants with AEs and SAEs as graded by the National Cancer Institute- Common Terminology Criteria for Adverse Events Version (NCI CTCAE 5.0)), including AEs that meet protocol-defined dose-limiting toxicity (DLT) criteria and AEs meeting protocol-defined adverse event of clinical interest (AECIs)
|
Up to approximately 2 years
|
|
Dose Escalation Phase:Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) of 3H-10000
Time Frame: Up to approximately 2 years
|
The MTD or MAD is defined as the highest dose evaluated for which the estimated toxicity rate is closest to a target toxicity rate, or the highest dose administered, respectively.
|
Up to approximately 2 years
|
|
Dose Escalation Phase:The recommended Phase 2 dose (RP2D) of 3H-10000
Time Frame: Up to approximately 2 years
|
The RP2D of 3H-10000 monotherapy will be determined based on relevant data, as available
|
Up to approximately 2 years
|
|
Efficacy Expansion Phase:Overall Response Rate (ORR)
Time Frame: Up to approximately 2 years
|
ORR is defined as the percentage of participants with confirmed complete response (CR) or partial response (PR) by Response Evaluations Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
|
Up to approximately 2 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Dose Escalation Phase:ORR
Time Frame: Up to approximately 2 years
|
ORR is defined as the percentage of participants with CR or PR, as determined by RECIST v1.1
|
Up to approximately 2 years
|
|
Dose Escalation Phase and Efficacy Expansion Phase:Disease Control Rate (DCR)
Time Frame: Up to approximately 2 years
|
DCR is defined as the percentage of participants with best overall response of a CR, PR, and stable disease, as assessed by RECIST v1.1
|
Up to approximately 2 years
|
|
Dose Escalation Phase and Efficacy Expansion Phase:Duration of Response (DOR)
Time Frame: Up to approximately 2 years
|
DOR is defined as the time from the first determination of an objective response per RECIST v1.1 until the first documentation of progression or death, whichever comes first, as assessed using RECIST v1.1
|
Up to approximately 2 years
|
|
Efficacy Expansion Phase:Progression Free Survival (PFS)
Time Frame: Up to approximately 2 years
|
PFS is defined as the time from the date of the first dose of study drug to the date of the first documentation of progressive disease assessed using RECIST v1.1 or death, whichever occurs first
|
Up to approximately 2 years
|
|
Efficacy Expansion Phase:Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: Up to approximately 2 years
|
Number of participants with AEs and SAEs as graded by the National Cancer Institute- Common Terminology Criteria for Adverse Events Version (NCI CTCAE 5.0), and AEs meeting protocol-defined adverse event of clinical interest (AECI)s.
|
Up to approximately 2 years
|
|
Dose Escalation Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Twice in the first 3 months
|
AUC0-last
|
Twice in the first 3 months
|
|
Dose Escalation Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Twice in the first 3 months
|
AUC0-inf
|
Twice in the first 3 months
|
|
Dose Escalation Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Twice in the first 3 months
|
Cmax
|
Twice in the first 3 months
|
|
Dose Escalation Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Twice in the first 3 months
|
Tmax
|
Twice in the first 3 months
|
|
Dose Escalation Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Twice in the first 3 months
|
Ctrough
|
Twice in the first 3 months
|
|
Dose Escalation Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Twice in the first 3 months
|
CL
|
Twice in the first 3 months
|
|
Dose Escalation Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Twice in the first 3 months
|
t1/2
|
Twice in the first 3 months
|
|
Dose Escalation Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Twice in the first 3 months
|
Vd
|
Twice in the first 3 months
|
|
Dose Escalation Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Twice in the first 3 months
|
Vss
|
Twice in the first 3 months
|
|
Efficacy Expansion Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Up to approximately 2 years
|
AUC0-last
|
Up to approximately 2 years
|
|
Efficacy Expansion Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Up to approximately 2 years
|
AUC0-inf
|
Up to approximately 2 years
|
|
Efficacy Expansion Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Up to approximately 2 years
|
Cmax
|
Up to approximately 2 years
|
|
Efficacy Expansion Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Up to approximately 2 years
|
Tmax
|
Up to approximately 2 years
|
|
Efficacy Expansion Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Up to approximately 2 years
|
Ctrough
|
Up to approximately 2 years
|
|
Efficacy Expansion Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Up to approximately 2 years
|
CL
|
Up to approximately 2 years
|
|
Efficacy Expansion Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Up to approximately 2 years
|
t1/2
|
Up to approximately 2 years
|
|
Efficacy Expansion Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Up to approximately 2 years
|
Vd
|
Up to approximately 2 years
|
|
Efficacy Expansion Phase:To evaluate the pharmacokinetics (PK) of 3H-10000
Time Frame: Up to approximately 2 years
|
Vss
|
Up to approximately 2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 3H-10000-101
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.